Clinical oncology (Royal College of Radiologists (Great Britain))
Two Versus Five-Fraction Magnetic Resonance-Guided Adaptive Radiotherapy with DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2): Interim Acute Toxicity Analysis of the Phase II Randomised Trial.
R Romrattaphan, P Dankulchai, T Prasartseree, W Sittiwong, W Thaweerat, S Junlabut, S Nitipitch
Published: 202510.1016/j.clon.2025.104029
Abstract
AIMS: DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2) is a phase II randomised controlled trial comparing two ultra-hypofractionated radiotherapy with dominant intraprostatic lesion (DIL) boost: 26 Gy/2F, 32 Gy to DIL vs 36.25 Gy/5F, 40…
Preview only. Read the full abstract at the source